Standard antidepressants taken at prescribed doses do not produce a high. SSRIs like sertraline or fluoxetine, the most commonly prescribed class, work gradually over weeks and have no immediate euphoric effect. But the full picture is more complicated: a handful of antidepressants have real abuse potential when taken in ways they were not designed for, and one newer treatment can produce altered states even at its approved dose.
Why Typical Antidepressants Do Not Produce Euphoria
The drugs most people think of when they hear “antidepressant” are SSRIs and SNRIs. These medications work by blocking the reuptake of serotonin (and in the case of SNRIs, norepinephrine), gradually shifting the brain’s chemistry over a period of weeks. Clinical doses of SSRIs occupy a large percentage of the serotonin transporter in the brain, but the therapeutic effect unfolds slowly through downstream changes that researchers still do not fully understand.1Translational Psychiatry. Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial That slow onset is the key reason SSRIs do not get people high. Drugs that produce euphoria tend to flood the brain’s reward circuits with dopamine rapidly, like a surge. SSRIs do not do that. They nudge serotonin levels upward, and any changes in mood are incremental, subtle, and often take two to six weeks to become noticeable.
This is why people starting an SSRI frequently report feeling nothing at all for the first few weeks, or even feeling worse before they feel better. The pharmacology simply is not built for an immediate reward signal. That said, “antidepressants” is a broad category covering drugs with very different mechanisms, and some of them interact with the brain’s reward pathways in ways that do create abuse risk.
Bupropion and Its Stimulant-Like Potential
Bupropion (sold under brand names like Wellbutrin and Zyban) is the antidepressant most frequently linked to misuse. Its chemical structure resembles amphetamines and synthetic cathinones, and at therapeutic doses it works by blocking the reuptake of norepinephrine and dopamine. When taken as prescribed, bupropion does not produce a high. But when crushed and snorted, injected, or consumed at many times the recommended dose, it can produce stimulant-like effects and euphoria.2PubMed Central. Bupropion abuse and overdose
This problem has been especially well documented in correctional facilities, where access to traditional stimulants is limited. When bupropion is crushed and snorted, it reaches the brain faster and binds to dopamine and norepinephrine receptors with higher affinity than when it is swallowed as a pill, which heightens its misuse potential.3PubMed. Bupropion diversion and misuse in the correctional facility Some prisons have responded by restricting bupropion prescriptions or switching to formulations that are harder to crush.
The distinction matters here: bupropion at prescribed doses is a legitimate, effective antidepressant and smoking-cessation aid. The abuse potential emerges when people deliberately circumvent the way the drug is designed to be absorbed. Swallowing a standard tablet delivers the drug slowly through the gut and liver. Snorting or injecting it bypasses those safeguards and delivers a concentrated dopamine hit that the pill form was never meant to produce.
Tianeptine and Opioid-Like Highs
Tianeptine is an unusual antidepressant that operates on the brain’s opioid receptors rather than the serotonin or dopamine systems. It is prescribed in parts of Europe, Asia, and Latin America, but it is not FDA-approved in the United States. At normal doses, it has antidepressant and anti-anxiety effects. But misuse of tianeptine at high doses can produce euphoria that feels similar to opioids, and chronic users can develop dependence and tolerance.4PubMed Central. Tianeptine, an Antidepressant with Opioid Agonist Effects: Pharmacology and Abuse Potential, a Narrative Review
In the U.S., tianeptine has been sold online and in gas stations under brand names like “ZaZa” and “Tianna,” marketed as dietary supplements. Several states have moved to ban or regulate it after reports of addiction, withdrawal symptoms resembling opioid withdrawal, and overdose deaths. For someone encountering tianeptine without knowing its pharmacology, the opioid-like effects can be genuinely surprising and genuinely dangerous. It does not look or feel like what most people expect from an “antidepressant.”
Venlafaxine Misuse at Extreme Doses
Venlafaxine (Effexor) is a mainstream SNRI prescribed to millions of people for depression and anxiety. At standard doses, it does not produce any euphoria. But there are documented cases of people deliberately taking ten to fifteen times the prescribed dose, or crushing and snorting the drug, to chase stimulant and psychedelic effects that some online communities have compared to MDMA or amphetamines.5PubMed. Venlafaxine as the ‘baby ecstasy’? Literature overview and analysis of web-based misusers’ experiences
This is genuinely dangerous territory. At those doses, venlafaxine can cause seizures, cardiac arrhythmias, and serotonin syndrome. The “high” some users describe comes with severe medical risks that escalate unpredictably. Unlike bupropion, where the abuse mechanism is somewhat understood through its dopamine activity, the pharmacological basis for venlafaxine’s euphoric effects at extreme doses is less clear and the margin between a supratherapeutic dose and a life-threatening overdose is narrow.
Esketamine and Altered States at Approved Doses
Esketamine (brand name Spravato) is a nasal spray derived from ketamine, approved for treatment-resistant depression. Unlike every other antidepressant on this list, esketamine can produce dissociative and perception-altering effects at its standard clinical dose. In trials, roughly four out of ten patients experienced dissociation, and about a quarter experienced sedation.6PubMed Central. Managing dissociative symptoms following the use of esketamine nasal spray: a case report The risk of dizziness, numbness, and a sense of detachment from reality was several times higher than with placebo across randomized trials.7PubMed Central. Adverse Effects of Esketamine for the Treatment of Major Depression Disorder: Findings from Randomized Controlled Trials
Ketamine is a well-known recreational drug, and esketamine is its close chemical relative. The FDA recognized this abuse potential, which is why esketamine is only administered under medical supervision at certified clinics. Patients must stay for at least two hours after each dose so clinicians can monitor for dissociative episodes. You cannot fill a prescription and take it at home. These restrictions exist precisely because esketamine can alter perception in ways that overlap with what people mean by “getting high,” even when it is being used exactly as intended.
Newer antidepressant approaches continue to explore the NMDA receptor system that esketamine targets. Dextromethorphan-bupropion (AXS-05), an oral NMDA receptor antagonist currently under investigation, combines a different NMDA-blocking agent with bupropion to increase its availability in the body.8CNS Spectrums. Rapid Antidepressant Effects and MADRS Item Improvements With AXS-05 (DEXTROMETHORPHAN-BUPROPION), an Oral NMDA Receptor Antagonist in Major Depressive Disorder Whether these newer compounds will carry similar dissociative risks is an active area of research.
When Antidepressants Trigger Mania
There is another way antidepressants can produce something that resembles a high, and it is not intentional misuse at all. Some patients, particularly those with an underlying vulnerability to bipolar disorder, develop hypomania or mania as a direct reaction to antidepressant treatment. This is sometimes called antidepressant-induced hypomania/mania, and it can look a lot like euphoria from the outside: elevated mood, racing thoughts, decreased need for sleep, impulsive behavior, grandiosity.
In a large study of over 2,800 patients with major depression, roughly one in six had a history of this kind of antidepressant-induced mood elevation. These patients shared many clinical features with people diagnosed with bipolar disorder, including higher rates of mood lability, irritability during treatment, and symptoms that looked like mixed depressive-manic states.9PubMed. Antidepressant-induced hypomania/mania in patients with major depression: Evidence from the BRIDGE-II-MIX study For these patients, the “high” is not a feature of the drug working as intended. It is a sign that the diagnosis may need revision, or that a mood stabilizer should be added.
If you have recently started an antidepressant and find yourself feeling unusually energized, sleeping much less than usual, spending impulsively, or feeling dramatically different in a way that goes well beyond relief from depression, contact your prescriber. These symptoms are not a sign the medication is working well. They can escalate into a full manic episode that carries real consequences.
Serotonin Syndrome and Dangerous Combinations
Mixing antidepressants with other substances that boost serotonin can trigger serotonin syndrome, a medical emergency whose symptoms include agitation, confusion, rapid heart rate, high blood pressure, muscle rigidity, tremors, and sweating.10PubMed Central. Serotonin syndrome: An often-neglected medical emergency This is relevant to the “getting high” question because some of the most dangerous interactions happen when people combine their prescribed antidepressant with recreational drugs.
Cocaine, MDMA, and certain opioids all have serotonergic activity. A case report documented serotonin syndrome in a 20-year-old man who took an overdose of the SSRI escitalopram while also using cocaine.11PubMed Central. Serotonin syndrome with escitolapram and concomitant use of cocaine: a case report Even combinations that individually seem manageable can become dangerous when both substances push serotonin levels in the same direction. There have been cases of serotonin syndrome from combining a standard SNRI like venlafaxine with opioids like oxycodone in elderly patients.12PubMed Central. Altered Mental Status in an Octogenarian: How Frequently Should Serotonin Syndrome Be Considered?
Some of the early symptoms of serotonin syndrome, like agitation and altered mental status, might even be mistaken for being “high” by someone who does not realize what is happening. The critical difference is that serotonin syndrome can progress to seizures, dangerously high body temperature, and death. Anyone on an antidepressant who uses recreational substances is playing with a particular kind of fire, and this risk is chronically underappreciated.
Emotional Blunting: When the Problem Is Feeling Too Little
For many people on antidepressants, the experience is the opposite of a high. Roughly 40 to 60 percent of antidepressant users report a phenomenon called emotional blunting, where feelings seem dulled, flattened, or muted. People describe having thoughts about events rather than genuine feelings, a disconnect from their own emotional responses, and sometimes a sense that their personality has fundamentally changed.13Psychopharmacology Institute. Antidepressant-Induced Emotional Blunting: Diagnosis, Mechanisms and Management
This matters in the context of the “can antidepressants make you high” question because it highlights how far the typical antidepressant experience is from euphoria. The most common complaint is not too much feeling but too little. People who expected that antidepressants would make them feel happy or elevated often find the reality deeply underwhelming, or even distressing in a different way than their depression was. Emotional blunting is a leading reason people stop taking their medication, which can be a significant clinical problem if the underlying depression returns.
Activation Syndrome in Young People
In children and adolescents, SSRIs sometimes produce a reaction called activation syndrome that can look alarming and might be misinterpreted as a drug-induced high. The symptoms include impulsiveness, restlessness, increased activity, insomnia, irritability, disinhibition, and agitation.14Revista Colombiana de Psiquiatría. Activation syndrome in children and adolescents treated with selective serotonin reuptake inhibitors A teenager who becomes suddenly energized, impulsive, and disinhibited after starting an SSRI might look to a parent like they are on something. But this is not euphoria or recreational drug use. It is a recognized adverse reaction that usually emerges in the first weeks of treatment and warrants immediate clinical attention because of its association with increased risk of self-harm in young patients.
Activation syndrome is distinct from the antidepressant-induced mania discussed earlier, though the two can overlap. It tends to be more agitation than elation, more wired than happy. Parents and caregivers should know to watch for this cluster of symptoms early in treatment and report it promptly rather than assuming the medication is “working.”
Older Antidepressants and Their Unusual Pharmacology
Tricyclic antidepressants (TCAs) like amitriptyline, which were the mainstay of depression treatment before SSRIs arrived, have their own set of mind-altering risks. At high plasma levels, TCAs can cause anticholinergic delirium, a state of confusion, disorientation, and sometimes hallucinations. In one study, patients whose plasma levels of amitriptyline exceeded a certain threshold were far more likely to develop this drug-induced delirium.15PubMed. Tricyclic-antidepressant-induced delirium and plasma drug concentration A case report described this complication in a previously healthy 36-year-old man who resumed a high dose of amitriptyline after abruptly stopping it.16PubMed Central. Tricyclic Antidepressant-Induced Anticholinergic Delirium in a Young Healthy Male Individual This is not a “high” in any pleasurable sense. It is a medical emergency that can include psychosis-like symptoms.
Monoamine oxidase inhibitors (MAOIs), another older class of antidepressant, have a different angle on this question. Some MAOIs, particularly tranylcypromine, have a chemical structure similar to amphetamine, which has raised questions about abuse potential. The mechanism of action is different from amphetamines, so the pharmacological basis for any euphoric effect remains unclear.17PubMed Central. Abuse and misuse of antidepressants Another MAOI, selegiline, is metabolized into l-methamphetamine and l-amphetamine in the body.18PubMed. Detection of l-Methamphetamine and l-Amphetamine as Selegiline Metabolites These are the “left-handed” mirror-image forms of the well-known stimulants, and they are far less potent at producing euphoria than their “right-handed” counterparts. Still, their presence in the body can complicate drug testing and raises theoretical questions about whether high-dose MAOIs could produce stimulant-like effects.
Antidepressants and False Positive Drug Tests
Even when antidepressants do not produce any subjective high, they can create practical headaches by triggering false positive results on urine drug screens. Bupropion is the worst offender here. In one analysis of urine drug screens that initially tested positive for amphetamines but failed confirmatory testing, bupropion was the most common cause, accounting for about four in ten of the false positives.19PubMed Central. Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay
This is not a trivial issue. People on bupropion who are subject to workplace drug testing, parole requirements, or custody evaluations can find themselves explaining a positive amphetamine screen that has nothing to do with drug use. The initial immunoassay screens used in most rapid drug tests are not specific enough to distinguish bupropion metabolites from actual amphetamines. A confirmatory test using more precise methods will clear the false positive, but the burden of requesting and waiting for that confirmation falls on the person being tested. If you take bupropion and are subject to drug screening, it is worth disclosing the prescription to whoever administers the test before results come back.
Withdrawal, Dependence, and the Language of Addiction
One area of persistent confusion is whether antidepressants are “addictive.” People sometimes conflate the withdrawal symptoms that can occur when stopping an antidepressant with addiction, and the discomfort of withdrawal gets folded into assumptions that the drugs must produce some kind of high. The reality is that physical dependence and addiction are not the same thing. Many medications, from blood pressure drugs to corticosteroids, cause withdrawal symptoms if stopped abruptly without producing any euphoria or craving. There is an ongoing debate in psychopharmacology about how to characterize antidepressant withdrawal, with some researchers arguing that the prevalence and severity of withdrawal have been underappreciated for years.20PubMed Central. Antidepressants, withdrawal, and addiction; where are we now?
But experiencing discontinuation symptoms like dizziness, irritability, brain zaps, or flu-like feelings after stopping an SSRI does not mean the drug was producing a high during treatment. It means the brain adapted to its presence and needs time to readjust. The subjective experience of antidepressant withdrawal is almost universally described as unpleasant, which is the opposite of what happens with drugs people take recreationally. Nobody seeks out SSRI withdrawal for fun.
The specific antidepressants discussed earlier in this article, bupropion and tianeptine in particular, are genuine exceptions where something closer to traditional addiction patterns has been documented. But extending that concern to SSRIs or SNRIs as a class overstates the evidence considerably. If your doctor tells you that your sertraline is not addictive, they are correct in the meaningful sense of the word, even if stopping it abruptly would be a bad idea.